Jiangxi Fushine Pharmaceutical Co., Ltd.
300497.SZ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.33B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.33 Billion |
|---|---|
| Enterprise Value | $8.42 Billion |
| Annual dividend | $0.05 |
| Dividend yield | 0.37% |
| Earnings per Share | $-0.1 |
| Beta | 0.17 |
| Outstanding Shares | 538,648,934 |
Return
| Return on Equity | 16.01% |
|---|---|
| Return on Assets | 8.52% |
| Return on Invested Capital | 13.54% |
Valuation & Multiples
| P/E Ratio | 17.98 |
|---|---|
| PEG | -3.56 |
| Price to Sales | 4.53 |
| Price to Book Ratio | 3.4 |
| Enterprise Value to Revenue | 4.28 |
| Enterprise Value to EBIT | 17.96 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 26, 2026
EPS
$0.42
ReportedRevenue
$661.89 M
Est. $661.89 MNext Earnings Call
Expected Date
May 3, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Jiangxi Fushine Pharmaceutical Co., Ltd.
1,663 employees
CEO: Jian Hua Bao
Jiangxi Fushine Pharmaceutical Co., Ltd. is engaged in the global research, development, production, and marketing of active pharmaceutical ingredients (APIs) and key chemical compounds for drug synthesis. Its product portfolio includes ...